BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S, Fiorino G, Peyrin-biroulet L. Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:1280-1290.e1. [DOI: 10.1016/j.cgh.2020.01.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Caron B, Jairath V, D'Amico F, Paridaens K, Magro F, Danese S, Peyrin-Biroulet L. Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. United European Gastroenterol J 2022. [PMID: 36029157 DOI: 10.1002/ueg2.12283] [Reference Citation Analysis]
2 Hu W, Fang T, Chen X. Identification of Differentially Expressed Genes and miRNAs for Ulcerative Colitis Using Bioinformatics Analysis. Front Genet 2022;13:914384. [DOI: 10.3389/fgene.2022.914384] [Reference Citation Analysis]
3 Zhao Y, Xue P, Lin G, Tong M, Yang J, Zhang Y, Ran K, Zhuge D, Yao Q, Xu H. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomater 2022;143:233-52. [PMID: 35245681 DOI: 10.1016/j.actbio.2022.02.039] [Reference Citation Analysis]
4 Ma L, Yu J, Zhang H, Zhao B, Zhang J, Yang D, Luo F, Wang B, Jin B, Liu J. Effects of Immune Cells on Intestinal Stem Cells: Prospects for Therapeutic Targets. Stem Cell Rev and Rep. [DOI: 10.1007/s12015-022-10347-7] [Reference Citation Analysis]
5 Pudipeddi A, Ko Y, Paramsothy S, Leong RW. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therap Adv Gastroenterol 2022;15:175628482210807. [DOI: 10.1177/17562848221080793] [Reference Citation Analysis]
6 Zhu X, Yang Y, Gao W, Jiang B, Shi L. Capparis spinosa Alleviates DSS-Induced Ulcerative Colitis via Regulation of the Gut Microbiota and Oxidative Stress. Evid Based Complement Alternat Med 2021;2021:1227876. [PMID: 34956375 DOI: 10.1155/2021/1227876] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Desalermos A, Pimienta M, Kalligeros M, Shehadeh F, Diamantopoulos L, Karamanolis G, Caldera F, Farraye FA. Safety of Immunizations for the Adult Patient With Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021:izab266. [PMID: 34849941 DOI: 10.1093/ibd/izab266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00294-6. [PMID: 34798038 DOI: 10.1016/S2468-1253(21)00294-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
9 Shao J, Li Z, Gao Y, Zhao K, Lin M, Li Y, Wang S, Liu Y, Chen L. Construction of a "Bacteria-Metabolites" Co-Expression Network to Clarify the Anti-Ulcerative Colitis Effect of Flavonoids of Sophora flavescens Aiton by Regulating the "Host-Microbe" Interaction. Front Pharmacol 2021;12:710052. [PMID: 34721011 DOI: 10.3389/fphar.2021.710052] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
10 Wang Z, Xue R, Lv M, Qi Y, Yu W, Xie Z, Chen W, Wang X, Tian X, Han B. Stepwise tracking strategy to screen ingredient from Galla Chinensis based on the "mass spectrometry guided preparative chromatography coupled with systems pharmacology". J Ethnopharmacol 2021;284:114533. [PMID: 34728319 DOI: 10.1016/j.jep.2021.114533] [Reference Citation Analysis]
11 Kłos P, Dabravolski SA. The Role of Mitochondria Dysfunction in Inflammatory Bowel Diseases and Colorectal Cancer. Int J Mol Sci 2021;22:11673. [PMID: 34769108 DOI: 10.3390/ijms222111673] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Shahrokh S, Qobadighadikolaei R, Abbasinazari M, Haghazali M, Asadzadeh Aghdaei H, Abdi S, Balaii H, Khanzadeh-Moghaddam N, Zali MR. Efficacy and Safety of Melatonin as an Adjunctive Therapy on Clinical, Biochemical, and Quality of Life in Patients with Ulcerative Colitis. Iran J Pharm Res 2021;20:197-205. [PMID: 34567156 DOI: 10.22037/ijpr.2020.113822.14508] [Reference Citation Analysis]
13 Kochar B, Pate V, Kappelman MD, Long MD, Ananthakrishnan AN, Chan AT, Sandler RS. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-TNF Agents in Older Adults. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00927-7. [PMID: 34481954 DOI: 10.1016/j.cgh.2021.08.047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ye L, Lin Y, Fan XD, Chen Y, Deng Z, Yang Q, Lei X, Mao J, Cui C. Identify Inflammatory Bowel Disease-Related Genes Based on Machine Learning. Front Cell Dev Biol 2021;9:722410. [PMID: 34381790 DOI: 10.3389/fcell.2021.722410] [Reference Citation Analysis]
15 Moradi S, Zobeiri M, Feizi A, Clark CCT, Entezari MH. The effects of spirulina (Arthrospira platensis) supplementation on anthropometric indices, blood pressure, sleep quality, mental health, fatigue status and quality of life in patients with ulcerative colitis: A randomised, double-blinded, placebo-controlled trial. Int J Clin Pract 2021;:e14472. [PMID: 34107141 DOI: 10.1111/ijcp.14472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Reeves MA, Royal JM, Morris DA, Jurkiewicz JM, Matoba N, Hamorsky KT. Spray-Dried Formulation of Epicertin, a Recombinant Cholera Toxin B Subunit Variant That Induces Mucosal Healing. Pharmaceutics 2021;13:576. [PMID: 33919585 DOI: 10.3390/pharmaceutics13040576] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol 2020;55:141-50. [PMID: 33254032 DOI: 10.1016/j.coph.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
18 Gwyer Findlay E, Sutton G, Ho G. The MARVEL trial: a phase 2b randomised placebo-controlled trial of oral MitoQ in moderate ulcerative colitis. Immunotherapy Advances 2021;1:ltaa002. [DOI: 10.1093/immadv/ltaa002] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yu T, Li Z, Xu L, Yang M, Zhou X. Anti-inflammation effect of Qingchang suppository in ulcerative colitis through JAK2/STAT3 signaling pathway in vitro and in vivo. J Ethnopharmacol 2021;266:113442. [PMID: 33027643 DOI: 10.1016/j.jep.2020.113442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
20 Costrini NV. Clearing of the Clouds in Inflammatory Bowel Disease Management. Dig Dis Sci 2020;65:3411-7. [PMID: 33009978 DOI: 10.1007/s10620-020-06635-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
22 D'Amico F, Solitano V, Peyrin-Biroulet L, Danese S. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next? Expert Opin Biol Ther 2021;21:47-55. [PMID: 32857634 DOI: 10.1080/14712598.2020.1817374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Parigi TL, D'Amico F, Peyrin-Biroulet L, Danese S. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opin Biol Ther 2021;21:37-46. [PMID: 32799561 DOI: 10.1080/14712598.2020.1811849] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
24 Zhang J, Shi G. Lymphocyte infiltration and key differentially expressed genes in the ulcerative colitis. Medicine (Baltimore) 2020;99:e21997. [PMID: 32871953 DOI: 10.1097/MD.0000000000021997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
25 Zhao H, Qian YZ, Qian HH. Interleukin-12B gene rs6887695 and rs2288831 polymorphisms are associated with an increased risk of ulcerative colitis development in Chinese Han population: A case-control study. J Clin Lab Anal 2020;34:e23472. [PMID: 32666631 DOI: 10.1002/jcla.23472] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 De Filippis A, Ullah H, Baldi A, Dacrema M, Esposito C, Garzarella EU, Santarcangelo C, Tantipongpiradet A, Daglia M. Gastrointestinal Disorders and Metabolic Syndrome: Dysbiosis as a Key Link and Common Bioactive Dietary Components Useful for their Treatment. Int J Mol Sci 2020;21:E4929. [PMID: 32668581 DOI: 10.3390/ijms21144929] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
27 D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis. Expert Opin Drug Saf 2020;19:807-16. [PMID: 32441228 DOI: 10.1080/14740338.2020.1773430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
28 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, Danese S. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Rev Gastroenterol Hepatol 2020;14:765-73. [PMID: 32427002 DOI: 10.1080/17474124.2020.1772057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
30 Chen Q, Fang X, Yao N, Wu F, Xu B, Chen Z. Suppression of miR-330-3p alleviates DSS-induced ulcerative colitis and apoptosis by upregulating the endoplasmic reticulum stress components XBP1. Hereditas 2020;157:18. [PMID: 32386518 DOI: 10.1186/s41065-020-00135-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]